Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
Rituximab for the treatment of follicular non-Hodgkins lymphoma (maintenance treatment following response to first-line chemotherapy)
NICE recommends rituximab as a possible treatment to maintain remission in people with follicular non-Hodgkin's lymphoma.
You should be able to have rituximab maintenance treatment if your follicular non-Hodgkin's lymphoma has already responded to rituximab when given in combination with chemotherapy.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended rituximab maintenance because it is clinically proven to prolong remission and its benefits to patients justifies its cost.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
- None found
This page was last updated: 14 January 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA226 Rituximab fel triniaeth gynnal gyntaf ar gyfer lymffoma ffoliglaidd nad yw'n lymffoma Hodgkin: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.